181 related articles for article (PubMed ID: 36765779)
1. Circulating Chromosome Conformation Signatures Significantly Enhance PSA Positive Predicting Value and Overall Accuracy for Prostate Cancer Detection.
Pchejetski D; Hunter E; Dezfouli M; Salter M; Powell R; Green J; Naithani T; Koutsothanasi C; Alshaker H; Jaipuria J; Connor MJ; Eldred-Evans D; Fiorentino F; Ahmed H; Akoulitchev A; Winkler M
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765779
[TBL] [Abstract][Full Text] [Related]
2. Chromatin conformation changes in peripheral blood can detect prostate cancer and stratify disease risk groups.
Alshaker H; Mills R; Hunter E; Salter M; Ramadass A; Skinner BM; Westra W; Green J; Akoulitchev A; Winkler M; Pchejetski D
J Transl Med; 2021 Jan; 19(1):46. PubMed ID: 33509203
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer.
Tosoian JJ; Zhang Y; Xiao L; Xie C; Samora NL; Niknafs YS; Chopra Z; Siddiqui J; Zheng H; Herron G; Vaishampayan N; Robinson HS; Arivoli K; Trock BJ; Ross AE; Morgan TM; Palapattu GS; Salami SS; Kunju LP; Tomlins SA; Sokoll LJ; Chan DW; Srivastava S; Feng Z; Sanda MG; Zheng Y; Wei JT; Chinnaiyan AM;
JAMA Oncol; 2024 Apr; ():. PubMed ID: 38635241
[TBL] [Abstract][Full Text] [Related]
5. What is an acceptable false negative rate in the detection of prostate cancer?
Verbeek JFM; Roobol MJ;
Transl Androl Urol; 2018 Feb; 7(1):54-60. PubMed ID: 29594020
[TBL] [Abstract][Full Text] [Related]
6. New Screening Test Improves Detection of Prostate Cancer Using Circulating Tumor Cells and Prostate-Specific Markers.
Ried K; Tamanna T; Matthews S; Eng P; Sali A
Front Oncol; 2020; 10():582. PubMed ID: 32391268
[TBL] [Abstract][Full Text] [Related]
7. Comparing the Performance of Digital Rectal Examination and Prostate-specific Antigen as a Screening Test for Prostate Cancer: A Systematic Review and Meta-analysis.
Matsukawa A; Yanagisawa T; Bekku K; Kardoust Parizi M; Laukhtina E; Klemm J; Chiujdea S; Mori K; Kimura S; Fazekas T; Miszczyk M; Miki J; Kimura T; Karakiewicz PI; Rajwa P; Shariat SF
Eur Urol Oncol; 2024 Jan; ():. PubMed ID: 38182488
[TBL] [Abstract][Full Text] [Related]
8. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
9. Multiparametric MRI-Based Radiomics for Prostate Cancer Screening With PSA in 4-10 ng/mL to Reduce Unnecessary Biopsies.
Qi Y; Zhang S; Wei J; Zhang G; Lei J; Yan W; Xiao Y; Yan S; Xue H; Feng F; Sun H; Tian J; Jin Z
J Magn Reson Imaging; 2020 Jun; 51(6):1890-1899. PubMed ID: 31808980
[TBL] [Abstract][Full Text] [Related]
10. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.
Brown LC; Ahmed HU; Faria R; El-Shater Bosaily A; Gabe R; Kaplan RS; Parmar M; Collaco-Moraes Y; Ward K; Hindley RG; Freeman A; Kirkham A; Oldroyd R; Parker C; Bott S; Burns-Cox N; Dudderidge T; Ghei M; Henderson A; Persad R; Rosario DJ; Shergill I; Winkler M; Soares M; Spackman E; Sculpher M; Emberton M
Health Technol Assess; 2018 Jul; 22(39):1-176. PubMed ID: 30040065
[TBL] [Abstract][Full Text] [Related]
11. Prostate Cancer: Early Detection and Assessing Clinical Risk Using Deep Machine Learning of High Dimensional Peripheral Blood Flow Cytometric Phenotyping Data.
Cosma G; McArdle SE; Foulds GA; Hood SP; Reeder S; Johnson C; Khan MA; Pockley AG
Front Immunol; 2021; 12():786828. PubMed ID: 34975879
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
[TBL] [Abstract][Full Text] [Related]
13. Combining Prostate-Specific Antigen Parameters With Prostate Imaging Reporting and Data System Score Version 2.0 to Improve Its Diagnostic Accuracy.
Baruah SK; Das N; Baruah SJ; Rajeev TP; Bagchi PK; Sharma D; Phukan M
World J Oncol; 2019 Dec; 10(6):218-225. PubMed ID: 31921377
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic significance of prostate-specific antigen in defining indications for initial prostate biopsy].
Popov SV; Guseinov RG; Skryabin ON; Orlov IN; Martov AG
Urologiia; 2018 Jul; (3):92-97. PubMed ID: 30035426
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of a novel multivariate risk score to guide biopsy decision for the diagnosis of clinically significant prostate cancer.
Klocker H; Golding B; Weber S; Steiner E; Tennstedt P; Keller T; Schiess R; Gillessen S; Horninger W; Steuber T
BJUI Compass; 2020 Mar; 1(1):15-20. PubMed ID: 35474911
[TBL] [Abstract][Full Text] [Related]
16. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.
McKiernan J; Donovan MJ; Margolis E; Partin A; Carter B; Brown G; Torkler P; Noerholm M; Skog J; Shore N; Andriole G; Thompson I; Carroll P
Eur Urol; 2018 Dec; 74(6):731-738. PubMed ID: 30237023
[TBL] [Abstract][Full Text] [Related]
17. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
[TBL] [Abstract][Full Text] [Related]
18. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
[TBL] [Abstract][Full Text] [Related]
19. Hospital-based prostate cancer screening in vietnamese men with lower urinary tract symptoms: a classification and regression tree model.
Cuong NC; Vien NT; Thien NM; Hai PT; Dang TN
BMC Urol; 2022 Oct; 22(1):166. PubMed ID: 36309745
[TBL] [Abstract][Full Text] [Related]
20. Transition zone prostate specific antigen density improves prostate cancer detection in Iranian men.
Nowroozi M; Ayati M; Jamshidian H; Arbab A; Ghorbani H; Amini E; Hakima H; Salehi S; Ghadian A
Nephrourol Mon; 2015 Mar; 7(2):e26752. PubMed ID: 25821749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
